S. Dimitrijević

发表

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

A. D. Van den Abbeele, J. Fletcher, G. Demetri, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

D. Tuveson, G. Demetri, H. Joensuu, 2001, The New England journal of medicine.

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

A. D. Van den Abbeele, S. Silverman, D. Tuveson, 2002, The New England journal of medicine.

Prevalence of KIT expression in human tumors.

J. Kononen, G. Sauter, R. Simon, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.

J. Fletcher, G. Demetri, M. Heinrich, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characterization of Pneumonitis in Patients with Advanced Non-small Cell Lung Cancer Treated with Everolimus (RAD001)

L. Schwartz, W. Hayes, S. Dimitrijević, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors

Suzanne F. Jones, J. Baselga, F. Rojo, 2005 .

Use of computerized tomography (CT) as an early prognostic indicator of response to imatinib mesylate (IM) in patients with gastrointestinal stromal tumors (GIST).

A. D. Van den Abbeele, J. Manola, G. Demetri, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis

S. Dimitrijević, D. DeAngelo, I. Galinsky, 2022, Leukemia.

A phase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): Phase 1 results

J. Soria, S. Dimitrijević, H. Burris, 2008 .

Molecular pharmacodynamic (MPD) evaluation of dose and schedule of RAD001 (everolimus) in patients with operable prostate carcinoma (PC)

T. Roskams, S. Dimitrijević, E. Lerut, 2005 .

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

B. Bain, J. Melo, D. Marin, 2002, The New England journal of medicine.

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

Suzanne F. Jones, F. J. Ramos, J. Baselga, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib

G. Demetri, H. Joensuu, M. Heinrich, 2004 .

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.

M. van Glabbeke, A. Hagemeijer, R. Sciot, 2004, European journal of cancer.

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

Sigrid Stroobants, Sasa Dimitrijevic, Ian Judson, 2001, The Lancet.

The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations.

Shan Zeng, Cem Akin, Sasa Dimitrijevic, 2002, Blood.

18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).

J Nuyts, L Mortelmans, J. Nuyts, 2003, European journal of cancer.

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).

R. Herrmann, H. Hawle, S. Dimitrijević, 2018, European journal of cancer.

Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group.

Sigrid Stroobants, O. S. Nielsen, Sasa Dimitrijevic, 2002, European journal of cancer.

Management of malignant gastrointestinal stromal tumours.

G. Demetri, H. Joensuu, P. Roberts, 2002, The Lancet. Oncology.

Everolimus in Combination with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Chemotherapy: A Phase I Study Using a Novel, Adaptive Bayesian Dose-Escalation Model

B. Solomon, J. Wolf, S. Dimitrijević, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Kinase M utations a nd I matinib R esponse i n P atients W ith Metastatic G astrointestinal S tromal T umor

J. Fletcher, G. Demetri, S. Singer, 2003 .

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

A. D. Van den Abbeele, J. Fletcher, G. Demetri, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer.

R. Heist, S. Dimitrijević, D. Camidge, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data

G. Hoehn, M. Heinrich, M. von Mehren, 2021, BMC Cancer.

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.

G. Giaccone, F. Cappuzzo, F. Shepherd, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Imatinib: the first 3 years.

S. Silberman, S. Dimitrijević, R. Capdeville, 2002, European journal of cancer.

Phase II study of imatinib in patients with small cell lung cancer.

D. Dunlop, R. Salgia, C. Fletcher, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Tyrosine kinase inhibitor imatinib (STIS71) as an anticancer agent for solid tumours

H. Joensuu, S. Dimitrijević, 2001, Annals of medicine.

Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).

J. Fletcher, G. Demetri, R. Herrmann, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Downregulation of 18F-FDG Uptake in PET as an Early Pharmacodynamic Effect in Treatment of Non–Small Cell Lung Cancer with the mTOR Inhibitor Everolimus

R. Boellaard, G. Giaccone, Roman K. Thomas, 2009, Journal of Nuclear Medicine.

Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group

J. Verweij, M. Glabbeke, A. Oosterom, 2005, Cancer Chemotherapy and Pharmacology.

A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma

S. Dimitrijević, A. Stathis, D. Cunningham, 2021, HemaSphere.

G. Hoehn, M. Heinrich, M. von Mehren, 2021, BMC cancer.

AZURE: A Phase 1/2 Study of Blu-263 As Monotherapy and in Combination with Azacitidine in Patients with Advanced Systemic Mastocytosis

S. Dimitrijević, R. Scherber, J. Gotlib, 2022, Blood.

Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis

S. Dimitrijević, D. DeAngelo, I. Galinsky, 2022, Leukemia.

Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis

J. Panse, I. Dybedal, M. Deininger, 2022, Blood advances.

A phase I/II trial of the oral PKC-inhibitor PKC412 (PKC) in combination with imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM

M. Heinrich, C. Blanke, S. Dimitrijević, 2005 .

Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib.

G. Demetri, H. Joensuu, M. Heinrich, 2004, Blood.

A Dose-Escalation (DE) Study with Expansion Evaluating Safety, Pharmacokinetics and Efficacy of the Novel, Balanced PI3K/mTOR Inhibitor PQR309 in Patients with Relapsed or Refractory Lymphoma

S. Dimitrijević, A. Stathis, A. Wicki, 2016 .

A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results.

R. Herrmann, S. Dimitrijević, A. Stathis, 2015 .

Targeting mTOR/PI3K in Primary CNS Lymphoma (PCNSL)

S. Dimitrijević, U. Schlegel, P. Kiewe, 2016 .

Pharmacodynamics of RAD001 measured by early FDG PET in patients with recurrent NSCLC

G. Giaccone, Roman K. Thomas, T. Zander, 2008 .

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.

G. Giaccone, F. Shepherd, L. Crinò, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

B. Solomon, J. Wolf, S. Dimitrijević, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.